• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc. - Common Shares (NQ:CMND)

    1.690 -0.180 (-9.63%)
    Streaming Delayed Price Updated: 1:48 PM EDT, Jul 21, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 153,844
    Open 1.790
    Bid (Size) 1.680 (3,000)
    Ask (Size) 1.690 (100)
    Prev. Close 1.870
    Today's Range 1.670 - 1.793
    52wk Range 1.740 - 524.00
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
    From Clearmind Medicine Inc.
    Via GlobeNewswire

    Performance

    YTD
    -91.5%
    -91.5%
    1 Month
    -43.3%
    -43.3%
    3 Month
    -85.2%
    -85.2%
    6 Month
    -93.6%
    -93.6%
    1 Year
    -99.6%
    -99.6%

    More News

    Read More
    News headline image
    Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Advances Its Innovation with Newly Granted U.S. Patent, Enhancing Global Patent Strength
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Granted U.S. Patent for Binge Behavior Regulators
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Completes Dosing for Part A of its of FDA-Regulated Phase I/II Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    Monday's pre-market session: top gainers and losers ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Stocks to Watch: ANY, CMND, PRFX, OLOX, IGC Data Centers, AI, Quantum & Healthcare
    Via AB Newswire
    Topics Artificial Intelligence Energy Intellectual Property
    Monday's session: gap up and gap down stocks ↗
    Via Chartmill
    Top stock movements in today's session. ↗
    Via Chartmill
    Friday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    What's going on in today's session ↗
    Via Chartmill
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    Wondering what's happening in today's pre-market session? ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Announces 1-for-10 Reverse Share Split
    From Clearmind Medicine Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Clearmind Medicine Inc. - Common Shares publicly traded?
    Yes, Clearmind Medicine Inc. - Common Shares is publicly traded.
    What exchange does Clearmind Medicine Inc. - Common Shares trade on?
    Clearmind Medicine Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Clearmind Medicine Inc. - Common Shares?
    The ticker symbol for Clearmind Medicine Inc. - Common Shares is CMND on the Nasdaq Stock Market
    What is the current price of Clearmind Medicine Inc. - Common Shares?
    The current price of Clearmind Medicine Inc. - Common Shares is 1.690
    When was Clearmind Medicine Inc. - Common Shares last traded?
    The last trade of Clearmind Medicine Inc. - Common Shares was at 07/21/26 01:48 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.